drugset / Trial / NCT00984113

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

NCT00984113

Phase 1 Terminated 44 enrolled Portola Pharmaceuticals Novartis · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to determine the pharmacokinetics and safety of elinogrel and its metabolite in patients with mild, moderate, and severe renal impairment compared to healthy volunteers.

Timeline

Start
2009-09
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Elinogrel Small molecule 100 mg
Background Aspirin Small molecule 81 mg
Background Aspirin Small molecule 100 mg